Disclaimer
is pocket guide attempts to define principles of practice that should produce high-quality
patient care. It is applicable to specialists, primary care, and providers at all levels. is
pocket guide should not be considered exclusive of other methods of care reasonably directed at
obtaining the same results. e ultimate judgment concerning the propriety of any course of
conduct must be made by the clinician aer consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated
with the distributor of this clinical reference tool.
Sources
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de
Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA,
Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA,
Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/
AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the
management of blood cholesterol: a report of the American College of Cardiolog y/
American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018
Nov 10. doi: 10.1161/CIR.0000000000000625.
Copublished in Journal of the American College of Cardiolog y (2018), doi: https://
doi.org/10.1016/j.jacc.2018.11.003.
ACCCHO1913
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2019 All rights reserved
GuidelineCentral.com
Abbreviations
ABI, ankle-brachial index; ACS, acute coronary syndrome; AIDS, acquired
immunodeficiency syndrome; apoB, apolipoprotein B; ARR, absolute risk reduction;
ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CHD,
coronary heart disease; CK, creatine kinase; CKD, chronic kidney disease; COR, Class
of Recommendation; CTT, Cholesterol Treatment Trialists; CVD, cardiovascular
disease; eGFR, estimated glomerular filtration rate; FH, familial hypercholesterolemia;
HDL, high-density lipoprotein; HF, heart failure; HIV, human immunodeficiency virus;
LDL-C, low-density lipoprotein cholesterol; LOE, Level of Evidence; Lp(a), lipoprotein
(a); MI, myocardial infarction; PCE, pooled cohort equations; QALY, quality-adjusted
life-year; RA, rheumatoid arthritis; RCT, randomized controlled trials; RRR, relative risk
reduction; RWI, relationships with industry and other entities; SAMS, statin-associated
muscle symptoms; SR, systematic review; TC, total cholesterol; VLDL, very low-density
lipoprotein; VLDL-C, very low-density lipoprotein cholesterol
is pocket guideline is provided as part of the American Heart Association's
Check. Change. Control. Cholestrol ™ initiative with the goal of improving
cholesterol management in high risk and cholesterol patients. Sanofi Regeneron
is the national supporter of AHA's Check. Change. Control. Cholestrol ™.
Sanofi Regeneron did not participate in the development of this guideline.
